← The deskResearch & data
Julian Roth
Reads the methods section so you don't have to.
Julian Roth is a pen name used by a writer at Aminoscope, published by MEAS Partners, LLC. Julian covers the primary clinical literature — trial design, effect sizes, and the gap between headlines and what the data actually says. Every claim carries a citation you can verify.
What they cover
- Randomized controlled trials
- Effect size interpretation
- Clinical endpoints and surrogate markers
- GLP-1 receptor agonist trial data
- Statistical methods in weight-loss research
- Primary literature appraisal
Articles by Julian Roth
44 pieces- The CALERIE trial explained: what a 2-year test of caloric restriction actually showedLongevity
- The NIA Interventions Testing Program: the gold standard for longevity claimsLongevity
- Ecnoglutide (XW003): the cAMP-biased GLP-1 agonist and its China phase 3 dataGLP-1
- Semaglutide vs liraglutide: what the head-to-head trials actually showGLP-1
- Survodutide (BI 456906): the GLP-1 / glucagon dual agonist and its Phase 2 dataGLP-1
- Mazdutide: the GLP-1/glucagon dual agonist approved in ChinaGLP-1
- Amycretin: what the early GLP-1 + amylin co-agonist data actually showGLP-1
- Pemvidutide: the GLP-1/glucagon dual agonist betting on lean-mass preservationGLP-1
- Zepbound for sleep apnea: the first drug approved for OSA, and what the trials showGLP-1
- Semaglutide for MASH: what the ESSENCE trial and the FDA approval actually sayGLP-1
- Retatrutide vs tirzepatide vs semaglutide: the three-way, read honestlyGLP-1
- What Are Peptides? A Plain-Language Guide to the SciencePeptides
- Cagrilintide: the amylin analog behind CagriSema, on its own termsGLP-1
- TRT and Hematocrit: Why Testosterone Thickens the Blood, and What to Do About ItLongevity
- Foods That Increase Testosterone: What the Evidence Actually SupportsLongevity
- Testosterone Therapy for Women: What the Evidence Actually SupportsLongevity
- Boron: What the Evidence Actually Shows About the “Testosterone Mineral”Longevity
- Peptides for muscle growth: an evidence ranking of what actually worksPeptides
- Adipotide: the “fat-targeting” peptide that worked in monkeys — and damaged their kidneysPeptides
- Testosterone levels by age: the real reference ranges, honestly explainedLongevity
- What the semaglutide weight-loss trials actually showedGLP-1
- Oral semaglutide (Rybelsus): what the PIONEER trials actually showedGLP-1
- Tirzepatide vs semaglutide for weight loss: what the trials actually supportGLP-1
- GLP-1 medications and muscle: what the body-composition data actually showGLP-1
- Retatrutide: the triple agonist and what its Phase 2 data actually showGLP-1
- Orforglipron: the oral non-peptide GLP-1, and what the trials actually showGLP-1
- CagriSema: what the REDEFINE program actually showedGLP-1
- Peptides for weight loss: which ones actually work?Peptides
- Semaglutide results timeline: how long Wegovy really takes to workGLP-1
- Epitalon (epithalon): the honest evidence behind the telomerase and longevity claimsLongevity
- Tesamorelin vs sermorelin: two GHRH analogs, very different statusPeptides
- Sermorelin before and after: what the evidence actually showsPeptides
- Retatrutide vs tirzepatide: what the evidence actually showsGLP-1
- Enclomiphene vs clomid: is the purified isomer worth it?Longevity
- MK-677 vs sermorelin: oral secretagogue or injectable GHRH analog?Peptides
- Mounjaro vs Ozempic: what the head-to-head trial actually foundGLP-1
- Trulicity vs Ozempic: the head-to-head trial resultGLP-1
- Wegovy vs Saxenda: the head-to-head wasn't closeGLP-1
- Rybelsus vs Ozempic: same drug, pill versus injectionGLP-1
- Berberine vs metformin: same switch, very different evidenceLongevity
- Berberine vs Ozempic: why 'nature's Ozempic' is a mythLongevity
- Metformin vs Ozempic: different drugs, often used togetherGLP-1
- Mounjaro vs Zepbound: the same drug under two namesGLP-1
- Contrave vs Wegovy: the weight-loss gap is largeGLP-1